Vytorin meets CV endpoints in IMPROVE-IT trial

Vytorin ezetimibe/simvastatin from Merck & Co. Inc. (NYSE:MRK) met the primary and all secondary composite endpoints versus Zocor simvastatin alone in the intent-to-treat population of the Phase III IMPROVE-IT trial studying cardiovascular events among patients receiving the LDL cholesterol-lowering therapy.

At seven years, 32.7% of patients taking Vytorin and 34.7% of patients taking Zocor experienced cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, rehospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization (HR=0.936, p=0.016). ...